Pull to refresh
Logo
Daily Brief
Following
Why Sign Up
Giuseppe Accogli

Giuseppe Accogli

Chief Executive Officer, Chiesi Group

Appears in 1 story

Notable Quotes

Acquiring KalVista is a transformational step for our rare disease portfolio, said Accogli in the announcement.

Stories

Chiesi acquires KalVista as pharma deepens rare disease push

Money Moves

Leading the largest deal in company history

For decades, people with hereditary angioedema have had only one option when an attack hits: injecting themselves, often in panic, to stop swelling that can close their airway. Last summer, a pill changed that. On Tuesday, Italian drugmaker Chiesi Farmaceutici agreed to buy the pill's maker, KalVista Pharmaceuticals, for about $1.9 billion in cashβ€”the largest acquisition in Chiesi's 90-year history.

Updated 2 hours ago